![](https://endpts.com/wp-content/uploads/2022/10/Rachel-Humphrey-Lieping-Chen-Normunity-tile.jpg)
Normunity CEO Rachel Humphrey and founder Lieping Chen
PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors
In 2015, Lieping Chen — the I/O researcher whose early work established the PD-1/PD-L1 as a cancer target and the co-founder of Amplimmune, bought out by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.